Advertisement

SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETA-AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE

      Neurofilament light chain protein (NfL) levels in the cerebrospinal fluid (CSF) increase as a marker of neuronal injury. Recent studies show that blood-based NfL levels are higher in individuals with neurodegenerative conditions, including AD (Bacioglu et al., Neuron 2016, Mattsson et al., JAMA 2017). This suggests that serum NfL is a viable marker of neuronal injury in humans that could be used to monitor disease progression and disease-modifying treatments. To tests its utility, this study’s leverages a multimodal, longitudinal design to determine whether cross-sectional and longitudinal serum NfL values are associated with established AD neuroimaging biomarkers.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'